Heart valve study seeks hidden clues in rare amyloidosis link

NCT ID NCT07170306

Not yet recruiting Knowledge-focused Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will observe 143 older adults with severe aortic stenosis who are scheduled for a minimally invasive valve replacement procedure called TAVR. Researchers want to find out how many also have cardiac amyloidosis, a condition where abnormal proteins build up in the heart. They will compare health outcomes and track changes in blood markers over 12 months to better understand the link between these two heart conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: transcatheter aortic valve replacement (TAVR)
What this could lead to: If successful, this could help doctors better identify and treat patients with both aortic stenosis and cardiac amyloidosis, potentially improving survival and quality of life.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients, and TAVR carries standard procedural risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC STENOSIS TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

More trials for these conditions

Other studies related to the condition(s) this trial covers.